GlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021The Motley Fool • 05/28/20
GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 TestThe Motley Fool • 05/21/20
Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 testTechCrunch • 05/20/20
GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's TruvadaThe Motley Fool • 05/19/20
Glaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pillMarket Watch • 05/18/20
3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKlineInvestorPlace • 05/08/20
Here's Why Investors Should Follow Sanofi and GlaxoSmithKline's New Coronavirus CollaborationThe Motley Fool • 04/30/20
GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/29/20